Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - caffeine, quantity: 20 mg - injection, intravenous infusion - excipient ingredients: sodium citrate dihydrate; water for injections; citric acid monohydrate - cafnea injection is indicated for the short-term treatment of apnoea of prematurity in infants between 28 and 33 weeks gestational age.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - acetazolamide sodium, quantity: 549.5 mg (equivalent: acetazolamide, qty 500 mg) - injection, powder for - excipient ingredients: sodium hydroxide; hydrochloric acid - for adjunctive treatment of: oedema due to congestive heart failure; drug induced oedema; centrencephalic epilepsies (petit mal, unlocalised seizures); chronic simple (open-angle) glaucoma, secondary glaucoma and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - fluorescein sodium, quantity: 100 mg/ml - injection - excipient ingredients: hydrochloric acid; water for injections; sodium hydroxide - diagnostic: intravenous injection of sodium fluorescein dye followed by multiframe photography (angiography) or opthalmoscopic evaluation (angioscopy). used in evaluation of wide range of retinal and choroidal diseases. less commonly used to evaluate abnormalities of the optic nerve and iris. may be used in the diagnosis and management of macular and vascular (including diabetic) diseases.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - activated charcoal, quantity: 0.2 g/ml - suspension - excipient ingredients: propylene glycol; glycerol; sucrose; citric acid; purified water; sodium hydroxide - for the treatment of poisoning and drug overdosage by oral ingestion.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - activated charcoal, quantity: 40 mg/ml - injection, suspension - excipient ingredients: hydrochloric acid; sodium chloride; sodium hydroxide; water for injections - aid to the stereotactic or ultrasonic localising of small lesions of the breast for later surgical excision.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - acetylcysteine, quantity: 6 g - injection - excipient ingredients: sodium hydroxide; water for injections - as an antidote for paracetamol poisoning: acetadote injection is indicated in the treatment of paracetamol overdose to protect against hepatoxicity.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - hydrochlorothiazide, quantity: 25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; magnesium stearate; calcium hydrogen phosphate dihydrate; sunset yellow fcf aluminium lake - hypertension: may be used alone or in combination with other antihypertensive drugs. oedema: associated with congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis, chronic renal failure (see precautions), premenstrual tension, and drug induced oedema.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - probenecid, quantity: 500 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate; stearic acid; magnesium stearate; maize starch; microcrystalline cellulose; povidone; macrogol 8000; hypromellose; macrogol 400; titanium dioxide; sunset yellow fcf; polysorbate 80; quinoline yellow - indications as at 25 may 2000 : gout - probenecid is a uricosuric agent for the treatment of hyperuricaemia in all stages of gout and gouty arthritis except an acute attack. asymptomatic hyperuricaemia seems to occur in a significant percentage of relatives of gouty patients. probenecid may be given prophylactically to these people to forestall gouty attacks and urate deposition in tissues. by virtue of its effective uricosuric activity, probenecid may be used to control the hyperuricaemia induced or aggravated by many diuretics employed for the treatment of oedema and hypertension (e.g. thiazides and smiliar diuretics). b-lactam antibiotic therapy - probenecid is indicated for the elevation and prolongation of plasma levels by whatever route the antibiotic is given. a two-to-fourfold increase in plasma levels has been demonstrated for benzylpenicillin, phenoxymethylpenicillin, the synthetic penicillins, ampicillin, methicillin, oxacillin, cloxacillin, nafcillin, carbenicillin, and for the cephamycin, mefoxin (cefoxitin sodium, msd), and the cephalosporins, cephalothin, cephalexin and cephaloglycin. because of its mechanisim of action, probenecid is not recommended in conjunction with a b-lactam antibiotic in the presence of known renal impairment. concurrent treatment with cidofovir for cmv retinitis in hiv patients. probenecid is recommended to be administered concomitantly with cidofovir, as the combination reduces the potential for nephrotoxicity associated with cidofovir.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - naloxone hydrochloride dihydrate, quantity: 440 microgram (equivalent: naloxone hydrochloride?, qty 400 microgram) - injection - excipient ingredients: water for injections; sodium chloride; hydrochloric acid - narcan is indicated for the complete or partial reversal of narcotic depression, including respiratory depression, induced by opioids including natural and synthetic narcotics, propoxyphene, methadone and the narcotic antagonist analgesics: nalbuphine, pentazocine and butorphanol. narcan is also indicated for the diagnosis of suspected acute opioid overdosage.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - esmolol hydrochloride, quantity: 100 mg - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium acetate trihydrate; glacial acetic acid - supraventricular tachycardia - for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. esmolol is also indicated in non-compensatory sinus tachycardia where, in the physician's judgement, the rapid heart rate requires specific intervention. esmolol is not intended for use in chronic settings where transfer to another agent is anticipated, or for treatment periods greater than 24 hours duration.